Riociguat tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Adempas
- Company
- Bayer AG (EU authorization holder)
- Medicine type
- Chemical medicine
- Therapeutic area
- Cardiovascular
- Indications recorded in the public source
- European Union source summary: For adults with WHO functional class II or III chronic thromboembolic pulmonary hypertension that is inoperable or persists or recurs after surgery, to improve exercise capacity. Also for pulmonary arterial hypertension with functional class II or III disease, alone or with an endothelin receptor antagonist in adults. Pediatric use has age, weight, formulation and combination requirements; see the linked EU product information.
- Indication source and scope
- European Union product information accessed 2 November 2026; exact revision date not separately extracted.. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.ema.europa.eu/en/documents/product-information/adempas-epar-product-information_en.pdf
- Adempas — official European Union product information
Official prescribing information · European Union product information accessed 2 November 2026; exact revision date not separately extracted.
Full official PDF opened; medicine identity and relevant indication text checked. This overseas source does not establish the Chinese approved scope.
- Adempas — EMA assessment and product overview
Regulatory product overview · Accessed 2 November 2026
English regulatory reference; authorization holder is identified for the EU product, not a Chinese generic or biosimilar.
- FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Dongguan Donghua Hospital — public prices
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions